Released Aug 9, 2018, after the close
10-Q filed Aug 9, 2018, 40 days after period end · 0001564590-18-021018
Q2 2018 · 10-Q
Revenue$463.00K$463.00K +85.9% vs Q2 2017−59.8% vs Q1 2018
Net Income-$9.96M-$9.96M N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.69-$0.69 N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$9,971,000N/M
Operating Cash Flowderived-$8,641,000N/M
Margins · derived
Operating margin-2153.6%+1928.8 pt vs Q2 2017
Net margin-2150.3%+1532.0 pt vs Q2 2017
What the release said
The release
Same quarter
| Metric | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|
| Revenue | $463.00K | $249.00K | — |
| Net Income | -$9.96M | -$9.17M | -$6.06M |
| EPS Diluted | -$0.69 | -$36.21 | -$25.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR